Menu

Home / For Visitors / 2026 Exhibitor Product / Jakop (Tofacitinib) Extended Release Tablet

Jakop (Tofacitinib) Extended Release Tablet

Category: Pharmaceutical

Exhibitor: ORIENT PHARMA CO., LTD.

Booth No: L228

Characteristic

Tofacitinib OROS is a value-added formulation utilizing an Osmotic Controlled-Release Oral Delivery System (OROS), enabling steady, extended drug release. Bioequivalence studies demonstrated a perfect match to the reference listed drug (RLD), within the 80–125% range.

The global JAK inhibitor market was valued at USD 2.3 billion in 2023 and is projected to grow at a 22.6% CAGR, reaching USD 9.9 billion by 2030.

Tofacitinib OROS was submitted to the Taiwan FDA in December 2024 and completed the US FDA Paragraph IV non-infringement filing in February 2025.

Other Products

Products you may be interested in

Highest Rated Products

TOP